Literature DB >> 17052612

Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.

Mihaela Ginj1, Jörg S Schmitt, Jianhua Chen, Beatrice Waser, Jean-Claude Reubi, Marion de Jong, Stefan Schulz, Helmut R Maecke.   

Abstract

The prototypes for tumor targeting with radiolabeled peptides are derivatives of somatostatin. Usually, they primarily have high affinity for somatostatin receptor subtype 2 (sst2), and they have moderate affinity for sst5. We aimed at developing analogs that recognize different somatostatin receptor subtypes for internal radiotherapy in order to extend the present range of accessible tumors. We synthesized DOTA-octapeptides based on octreotide by replacing Phe3 mainly with unnatural amino acids. The affinity profile was determined by using cell lines transfected with sst1-5. Internalization was determined by using AR42J, HEK-sst3, and HEK-sst5 cell lines, and biodistribution was studied in rat tumor models. Two of the derivatives thus obtained showed an improved binding affinity profile, enhanced internalization into cells expressing sst2 and sst3, respectively, and better tumor:kidney ratios in animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052612     DOI: 10.1016/j.chembiol.2006.08.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  12 in total

1.  Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.

Authors:  Wenbing Dai; Wu Jin; Junlin Zhang; Xueqing Wang; Jiancheng Wang; Xuan Zhang; You Wan; Qiang Zhang
Journal:  Pharm Res       Date:  2012-06-22       Impact factor: 4.200

2.  Twins in spirit: DOTATATE and high-affinity DOTATATE.

Authors:  Claudia Brogsitter; Margret Schottelius; Klaus Zöphel; Jörg Kotzerke; Hans-Jürgen Wester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-21       Impact factor: 9.236

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 4.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 5.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

6.  Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.

Authors:  Xuejuan Wang; Melpomeni Fani; Stefan Schulz; Jean Rivier; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-29       Impact factor: 9.236

7.  Twins in spirit part II: DOTATATE and high-affinity DOTATATE--the clinical experience.

Authors:  Claudia Brogsitter; Klaus Zöphel; Holger Hartmann; Margret Schottelius; Hans-Jürgen Wester; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-15       Impact factor: 9.236

Review 8.  Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.

Authors:  Melpomeni Fani; Rosalba Mansi; Guillaume P Nicolas; Damian Wild
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

9.  DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst2,5 Receptors.

Authors:  Alessandro Pratesi; Mauro Ginanneschi; Marco Lumini; Anna M Papini; Ettore Novellino; Diego Brancaccio; Alfonso Carotenuto
Journal:  Front Chem       Date:  2017-02-23       Impact factor: 5.221

10.  Synergistic Catalysis by "Polymeric Microzymes and Inorganic Nanozymes": The 1+1>2 Effect for Intramolecular Cyclization of Peptides.

Authors:  Zhiliang Chen; Börje Sellergren; Xiantao Shen
Journal:  Front Chem       Date:  2017-09-26       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.